News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Immunotherapy’ clear

  • One-third of patients with metastatic melanoma in a phase 1 clinical trial have survived five years after treatment with the immunotherapy drug nivolumab, which blocks the PD-1 immune checkpoint, reports a Dana-Farber Cancer Institute scientist.

Tags: Melanoma, Immunotherapy

  • Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma.

Tags: Partnerships, Immunotherapy

  • New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

Tags: BasicResearch, Immunotherapy

  • The Department of Cancer Immunology and AIDS at Dana-Farber is changing its name to the Department of Cancer Immunology and Virology.

Tags: BasicResearch, Immunotherapy

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a Memorial Sloan Kettering clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia. Dana-Farber/Boston Children’s is the only site in New England to offer this breakthrough experimental approach that triggers a patient's immune system to attack cancer cells.

Tags: ChildhoodCancer, Immunotherapy

  • Dana-Farber researchers report in the New England Journal of Medicine that treating advanced melanoma patients initially with the combination of the immunotherapy drugs nivolumab and ipilimumab achieves a much higher response rate than treatment with ipilimumab alone.

Tags: Melanoma, Immunotherapy

  • Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

Tags: EGFR, Genomics, LungCancer, OvarianCancer, ProstateCancer, Lymphoma, Immunotherapy

  • A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.

Tags: MultipleMyeloma, Leukemia, Immunotherapy

  • Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Tags: Lymphoma, Immunotherapy

  • Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.

Tags: Melanoma, Immunotherapy

Showing 1-10 of 17 items